Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian ...

They’re meant to save money for the health care system, carve into pharma’s profits, and finally rid your television of some ...

The FDA has approved Selarsdi (ustekinumab-aken) as interchangeable to the reference product Stelara (ustekinumab).

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...

A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

Management’s $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like ...

Indian biopharma firm Biocon's profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar drugs in its key U.S. and European markets.

It would have been interesting to have sat in on the senior management meetings at Merck that thrashed out the Organon ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...